132 related articles for article (PubMed ID: 19978359)
1. Lymphocytic Leukæmia under Treatment by Benzol.
Rolleston HD; Boyd EJ
Proc R Soc Med; 1914; 7(Sect Study Dis Child):71-3. PubMed ID: 19978359
[No Abstract] [Full Text] [Related]
2. Time-to-progression after front-line fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy for chronic lymphocytic leukaemia: a retrospective, multicohort study.
Herling CD; Coombes KR; Benner A; Bloehdorn J; Barron LL; Abrams ZB; Majewski T; Bondaruk JE; Bahlo J; Fischer K; Hallek M; Stilgenbauer S; Czerniak BA; Oakes CC; Ferrajoli A; Keating MJ; Abruzzo LV
Lancet Oncol; 2019 Nov; 20(11):1576-1586. PubMed ID: 31582354
[TBL] [Abstract][Full Text] [Related]
3. Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.
Davids MS; Brander DM; Kim HT; Tyekucheva S; Bsat J; Savell A; Hellman JM; Bazemore J; Francoeur K; Alencar A; Shune L; Omaira M; Jacobson CA; Armand P; Ng S; Crombie J; LaCasce AS; Arnason J; Hochberg EP; Takvorian RW; Abramson JS; Fisher DC; Brown JR;
Lancet Haematol; 2019 Aug; 6(8):e419-e428. PubMed ID: 31208944
[TBL] [Abstract][Full Text] [Related]
4. Myelogenous Leukaemia-Treatment by Benzol and X-Ray.
Lafleur HA
Can Med Assoc J; 1920 Nov; 10(11):996-8. PubMed ID: 20312376
[No Abstract] [Full Text] [Related]
5. Benzol in the Treatment of Lymphatic Leukæmia.
Ross JN
Proc R Soc Med; 1914; 7(Sect Study Dis Child):129-32. PubMed ID: 19978278
[No Abstract] [Full Text] [Related]
6. Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study.
Michels N; Boer JM; Enshaei A; Sutton R; Heyman M; Ebert S; Fiocco M; de Groot-Kruseman HA; van der Velden VHJ; Barbany G; Escherich G; Vora A; Trahair T; Dalla-Pozza L; Pieters R; Zur Stadt U; Schmiegelow K; Moorman AV; Zwaan CM; den Boer ML
Lancet Haematol; 2021 Oct; 8(10):e700-e710. PubMed ID: 34560013
[TBL] [Abstract][Full Text] [Related]
7. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.
O'Brien S; Jones JA; Coutre SE; Mato AR; Hillmen P; Tam C; Österborg A; Siddiqi T; Thirman MJ; Furman RR; Ilhan O; Keating MJ; Call TG; Brown JR; Stevens-Brogan M; Li Y; Clow F; James DF; Chu AD; Hallek M; Stilgenbauer S
Lancet Oncol; 2016 Oct; 17(10):1409-1418. PubMed ID: 27637985
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic value of absolute monocyte count in chronic lymphocytic leukaemia].
Szerafin L; Jakó J; Riskó F
Orv Hetil; 2015 Apr; 156(15):592-7. PubMed ID: 25845318
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study.
den Boer ML; Cario G; Moorman AV; Boer JM; de Groot-Kruseman HA; Fiocco M; Escherich G; Imamura T; Yeoh A; Sutton R; Dalla-Pozza L; Kiyokawa N; Schrappe M; Roberts KG; Mullighan CG; Hunger SP; Vora A; Attarbaschi A; Zaliova M; Elitzur S; Cazzaniga G; Biondi A; Loh ML; Pieters R;
Lancet Haematol; 2021 Jan; 8(1):e55-e66. PubMed ID: 33357483
[TBL] [Abstract][Full Text] [Related]
10. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study.
Stilgenbauer S; Eichhorst B; Schetelig J; Coutre S; Seymour JF; Munir T; Puvvada SD; Wendtner CM; Roberts AW; Jurczak W; Mulligan SP; Böttcher S; Mobasher M; Zhu M; Desai M; Chyla B; Verdugo M; Enschede SH; Cerri E; Humerickhouse R; Gordon G; Hallek M; Wierda WG
Lancet Oncol; 2016 Jun; 17(6):768-778. PubMed ID: 27178240
[TBL] [Abstract][Full Text] [Related]
11. Intrinsic and treatment-related immune alterations in chronic lymphocytic leukaemia and their impact for clinical practice.
Dasanu CA
Expert Opin Pharmacother; 2008 Jun; 9(9):1481-94. PubMed ID: 18518779
[TBL] [Abstract][Full Text] [Related]
12. Two rare diagnoses during chronic lymphocytic leukaemia follow-up: Kaposi's sarcoma and Merkel cell carcinoma.
Dogu MH; Sari I; Hacioglu S; Degirmencioglu S; Şen N; Keskin A
Scott Med J; 2016 Feb; 61(1):60-3. PubMed ID: 27334532
[TBL] [Abstract][Full Text] [Related]
13. Using immunotherapy and novel trial designs to optimise front-line therapy in adult acute lymphoblastic leukaemia: breaking with the traditions of the past.
Short NJ; Kantarjian H
Lancet Haematol; 2023 May; 10(5):e382-e388. PubMed ID: 37003279
[TBL] [Abstract][Full Text] [Related]
14. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.
Jones JA; Mato AR; Wierda WG; Davids MS; Choi M; Cheson BD; Furman RR; Lamanna N; Barr PM; Zhou L; Chyla B; Salem AH; Verdugo M; Humerickhouse RA; Potluri J; Coutre S; Woyach J; Byrd JC
Lancet Oncol; 2018 Jan; 19(1):65-75. PubMed ID: 29246803
[TBL] [Abstract][Full Text] [Related]
15. Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial.
Brown JR; Hamadani M; Hayslip J; Janssens A; Wagner-Johnston N; Ottmann O; Arnason J; Tilly H; Millenson M; Offner F; Gabrail NY; Ganguly S; Ailawadhi S; Kasar S; Kater AP; Doorduijn JK; Gao L; Lager JJ; Wu B; Egile C; Kersten MJ
Lancet Haematol; 2018 Apr; 5(4):e170-e180. PubMed ID: 29550382
[TBL] [Abstract][Full Text] [Related]
16. Cost-minimisation analysis of chronic lymphocytic leukemia in Spain in the era of oral targeted therapies.
Montañés B; Casado G; Medina Á; Nieto P; Ramírez-Payer Á
Farm Hosp; 2022 Jan; 46(2):72-79. PubMed ID: 35379098
[TBL] [Abstract][Full Text] [Related]
17. Chronic lymphocytic leukaemia.
Dighiero G; Hamblin TJ
Lancet; 2008 Mar; 371(9617):1017-29. PubMed ID: 18358929
[TBL] [Abstract][Full Text] [Related]
18. Benzol in Leukæmia.
Hospital (Lond 1886); 1914 Dec; 57(1488):284. PubMed ID: 29823549
[No Abstract] [Full Text] [Related]
19. BENZOL THERAPY IN LEUKAEMIA AND LYMPHO-SARCOMA.
Moorhead TG
Br Med J; 1915 Mar; 1(2827):410-3. PubMed ID: 20767516
[No Abstract] [Full Text] [Related]
20. Chronic Myelocytic Leukæmia treated by Benzol, &c.
Weber FP
Proc R Soc Med; 1914; 7(Clin Sect):39-41. PubMed ID: 19977550
[No Abstract] [Full Text] [Related]
[Next] [New Search]
